BEAT — HeartBeam, Inc.

HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $21 million for the full year 2025, or $0.62 per share; Q4 net loss was $5.3 million, or $0.15 per share, in line with expectations.
• Operating Cash Outflows: Less than $14 million for the full year, with Q4 outflows at $2.9 million, reflecting a 3% decrease year-over-year and a 30% decrease compared to the same quarter last year.
• Cash Position: Cash and cash equivalents totaled $4.4 million as of December 31, 2025.
• 2026 Cash Flow Guidance: Expected operating cash outflows of approximately $17 million to $19 million, with a focus on maintaining a capital-efficient operating model.

2. Strategic Updates and Business Highlights

• FDA Clearances: Achieved 510(k) clearance for the 12-lead synthesis software in December 2025, enabling a limited commercial launch.
• Product Launch: Initiated a limited commercial launch focusing on concierge and preventive cardiology practices, targeting high-net-worth individuals.
• New Product Development: Unveiled a working prototype of a 12-lead patch designed to disrupt the $2 billion ambulatory cardiac monitoring market.
• Clinical Studies: Enrollment commenced for the ALIGN ACS study, comparing HeartBeam’s ECG to standard 12-lead ECGs for heart attack detection.
• AI Initiatives: Announced a strategic collaboration with Mount Sinai to develop AI algorithms for heart attack assessment and other clinical applications.

3. Forward Guidance and Outlook

• Commercial Strategy: Plans to validate the business model within a concentrated market before scaling to a broader audience. Aiming for cash flow breakeven with approximately 30,000 patients.
• Market Expansion: Initial focus on a small number of concierge practices, with plans to expand into larger patient-pay segments and telehealth networks by 2027.
• R&D Investments: Incremental investments of $3 million to $5 million anticipated in 2026 to support commercialization and product development.

4. Bad News, Challenges, or Points of Concern

• Regulatory Uncertainty: While the patch is likely to follow a 510(k) pathway, the regulatory path for heart attack detection remains uncertain, which could delay timelines.
• Market Competition: There is potential competition from other telehealth services and cardiac monitoring technologies, which may impact market penetration.
• Dependence on Concierge Market: Initial reliance on a niche market may limit growth potential until broader adoption is achieved.

5. Notable Q&A Insights

• ALIGN ACS Study Timeline: Expected rapid enrollment due to the study design, with completion anticipated by the end of Q3 2026, which will inform the pivotal study for FDA submission.
• Commercialization Focus: Emphasis on deep adoption within a small number of anchor accounts to validate the model before scaling.
• Profit-Sharing Models: Discussions around potential profit-sharing arrangements with practices as the company expands, though initial focus remains on direct subscription pricing.
• Interest in Telehealth Providers: Strong interest in partnerships with telehealth services, leveraging HeartBeam’s unique technology to enhance clinical-grade ECG offerings.

Overall, HeartBeam, Inc. is positioned for significant advancements in 2026, with a clear strategy to validate its technology and expand its market presence, despite facing regulatory uncertainties and competitive pressures.